Search Results - "Rastogi, Medini"

Secondary Impacts of Evidence-Based Treatment Training and Provision on Children’s Mental Health Care by Klein, Corinna C., Rastogi, Medini, Barnett, Miya L.

“…Training therapists in evidence-based treatments (EBTs) is a strategy for improving the quality of mental health care. State and county-wide initiatives have…”
Get full text

Corrigendum to Secondary Impacts of Evidence-Based Treatment Training and Provision on Children’s Mental Health Care [Children and Youth Services Review Volume 128(September 2021) 106136] by Klein, Corinna C., Rastogi, Medini, Barnett, Miya L.

“…The authors and the journal regret that the printed version of the above article contained a number of errors. The correct and final version follows. The…”
Get full text

Secondary impacts of evidence-based treatment training and provision on children’s mental health care by Klein, Corinna C., Rastogi, Medini, Barnett, Miya L.

“…•Parent-Child Interaction Therapy training impacts general child therapy practice.•Clients may receive secondary benefits from their therapists’ PCIT…”
Get full text

Therapist Experiences and Attitudes About Implementing Internet-Delivered Parent-Child Interaction Therapy During COVID-19 by Barnett, Miya L., Sigal, Marika, Green Rosas, Yessica, Corcoran, Frederique, Rastogi, Medini, Jent, Jason F.

“…•The vast majority of PCIT therapists transited to deliver iPCIT during COVID-19.•82% of therapists expressed interest in continuing with iPCIT after…”
Get full text

Single-dose 177 Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial by Aggarwal, Rahul, Starzinski, Stephanie, de Kouchkovsky, Ivan, Koshkin, Vadim, Bose, Rohit, Chou, Jonathan, Desai, Arpita, Kwon, Daniel, Kaushal, Samuel, Trihy, Lauren, Rastogi, Medini, Ippisch, Robin, Aslam, Maya, Friedlander, Terence, Feng, Felix, Oh, David, Cheung, Alexander, Small, Eric, Evans, Michael, Fong, Lawrence, Hope, Thomas A

“…Checkpoint inhibitors have been shown to have limited activity in patients with metastatic castration-resistant prostate cancer. We aimed to determine whether…”
Get full text

Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial by Aggarwal, Rahul, Starzinski, Stephanie, de Kouchkovsky, Ivan, Koshkin, Vadim, Bose, Rohit, Chou, Jonathan, Desai, Arpita, Kwon, Daniel, Kaushal, Samuel, Trihy, Lauren, Rastogi, Medini, Ippisch, Robin, Aslam, Maya, Friedlander, Terence, Feng, Felix, Oh, David, Cheung, Alexander, Small, Eric, Evans, Michael, Fong, Lawrence, Hope, Thomas A

“…Checkpoint inhibitors have been shown to have limited activity in patients with metastatic castration-resistant prostate cancer. We aimed to determine whether…”
Get full text

Immunogenic priming with 177 Lu-PSMA-617 plus pembrolizumab in metastatic castration resistant prostate cancer (mCRPC): A phase 1b study by Aggarwal, Rahul Raj, Luch Sam, Srey, Koshkin, Vadim S, Small, Eric Jay, Feng, Felix Y, de Kouchkovsky, Ivan, Kwon, Daniel H, Friedlander, Terence W., Borno, Hala, Bose, Rohit, Chou, Jonathan, Desai, Arpita, Rodvelt, Tammy J., Aslam, Maya, Rastogi, Medini, Fong, Lawrence, Hope, Thomas A

“…Abstract only 5053 Background: Immune checkpoint inhibitors have limited single agent activity in microsatellite-stable mCRPC. 177 Lu-PSMA-617 (Lu) is a…”
Get full text